fashion -WSS

fashion

author：comprehensive 2025-10-02 01:07:42 - browse：212

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： House panel to mark up pandemic

hotspot

focus

WSS

California man arrested in connection with serial murders of Mexican strip club workers

Argenx readies a blockbuster opportunity with drug for autoimmune disease

SCOTUS questions limit to govt efforts to fight misinformation

House panel to mark up pandemic

AstraZeneca to buy developer of next

SCOTUS questions limit to govt efforts to fight misinformation

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hepatitis C has a cure — but many Americans still lack access to it

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Affirmative action in medical school literally saved lives

How corporate America is slashing DEI workers amid backlash to diversity programs

New air purifier tech could be key to improving indoor air quality

App could help diagnose ear infections more accurately — and at home

Continuity nursing helped my family in our darkest PICU moments

Positive childhood experiences can help future health

How one medical school became remarkably diverse

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Wikipedia

Baby aspirin cuts fat buildup in liver disease patients, in small study

Another man arrested in connection with shooting at Kansas nightclub

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Sen. Bill Cassidy on how to lower drug prices

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

hotspot

focus

explore

Wikipedia